

# Adam C Yopp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5213724/publications.pdf>

Version: 2024-02-01

134  
papers

6,422  
citations

87888

38  
h-index

74163

75  
g-index

135  
all docs

135  
docs citations

135  
times ranked

9840  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. Clinical Gastroenterology and Hepatology, 2023, 21, 1091-1093.e3.	4.4	15
2	Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2023, 21, 1094-1096.e2.	4.4	22
3	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2022, 20, 1561-1569.e4.	4.4	52
4	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clinical Gastroenterology and Hepatology, 2022, 20, e1157-e1169.	4.4	12
5	Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, e267-e288.	4.4	32
6	Nativity Status is an Important Social Determinant of Health for Hispanic Patients with Gastric Cancer in Texas. Annals of Surgical Oncology, 2022, 29, 3113-3121.	1.5	4
7	Disparities in Guideline-Concordant Treatment and Survival Among Border County Residents With Gastric Cancer. JCO Oncology Practice, 2022, 18, e748-e758.	2.9	6
8	ASO Visual Abstract: Nativity Status is an Important Social Determinant of Health for Hispanic Patients with Gastric Cancer in Texas. Annals of Surgical Oncology, 2022, , .	1.5	0
9	Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. Journal of Translational Medicine, 2022, 20, 116.	4.4	3
10	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	1.3	17
11	Machine Learning Improves Prediction Over Logistic Regression on Resected Colon Cancer Patients. Journal of Surgical Research, 2022, 275, 181-193.	1.6	10
12	Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population. Annals of Surgical Oncology, 2022, 29, 5488-5497.	1.5	5
13	Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. Journal of Gastrointestinal Surgery, 2021, 25, 1815-1827.	1.7	13
14	Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 1925-1932.e1.	4.4	46
15	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clinical Gastroenterology and Hepatology, 2021, 19, 2379-2388.e6.	4.4	7
16	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut, 2021, 70, gutjnl-2020-321040.	12.1	48
17	Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver. Chinese Clinical Oncology, 2021, 10, 5-5.	1.2	4
18	Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1387-1395.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. Journal of Surgical Oncology, 2021, 123, 407-415.	1.7	8
20	Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. Annals of Surgical Oncology, 2021, 28, 1929-1936.	1.5	7
21	Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. Seminars in Liver Disease, 2021, 41, 001-008.	3.6	14
22	Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. Journal of Surgical Oncology, 2021, 123, 963-969.	1.7	6
23	Inaccurate Clinical Stage Is Common for Gastric Adenocarcinoma and Is Associated with Undertreatment and Worse Outcomes. Annals of Surgical Oncology, 2021, 28, 2831-2843.	1.5	10
24	Redefining High-Volume Gastric Cancer Centers: The Impact of Operative Volume on Surgical Outcomes. Annals of Surgical Oncology, 2021, 28, 4839-4847.	1.5	17
25	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2021, 28, 6551-6561.	1.5	11
26	Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. Hpb, 2021, 23, 422-433.	0.3	10
27	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdominal Radiology, 2021, 46, 3708-3716.	2.1	2
28	High Neutrophil-lymphocyte Ratio and Delta Neutrophil-lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Digestive Diseases and Sciences, 2021, , 1.	2.3	8
29	Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. Hpb, 2021, 23, 868-876.	0.3	7
30	The presentation of Hispanic gastric cancer patients varies by location of patient ancestry. Journal of Surgical Oncology, 2021, 124, 1051-1059.	1.7	5
31	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	4.4	31
32	Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 Pandemic. JCO Oncology Practice, 2021, 17, e1327-e1332.	2.9	20
33	Socioeconomic and racial/ethnic disparities in receipt of palliative care among patients with metastatic hepatocellular carcinoma. Journal of Surgical Oncology, 2021, 124, 1365-1372.	1.7	9
34	Treatment and Survival Disparities of Colon Cancer in the Texas-Mexico Border Population: Cancer Disparities in Border Population. Journal of Surgical Research, 2021, 267, 432-442.	1.6	4
35	Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. Journal of Magnetic Resonance Imaging, 2020, 51, 415-425.	3.4	57
36	Predictors and outcomes of converted minimally invasive pancreaticoduodenectomy: a propensity score matched analysis. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 544-550.	2.4	12

#	ARTICLE	IF	CITATIONS
37	Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 242-248.e5.	4.4	57
38	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. <i>Surgery</i> , 2020, 167, 352-357.	1.9	11
39	Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. <i>Annals of Surgical Oncology</i> , 2020, 27, 1997-2006.	1.5	16
40	Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays. <i>Hepatology</i> , 2020, 72, 1085-1101.	7.3	16
41	The Evolving Landscape of Hepatocellular Carcinoma. <i>American Surgeon</i> , 2020, 86, 865-872.	0.8	4
42	Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. <i>Clinical Imaging</i> , 2020, 67, 146-151.	1.5	4
43	Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. <i>Surgical Oncology</i> , 2020, 35, 120-125.	1.6	8
44	Hospital variation in use of prophylactic drains following hepatectomy. <i>Hpb</i> , 2020, 22, 1471-1479.	0.3	0
45	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	3.7	21
46	Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 701-709.	3.7	45
47	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020, 72, 1654-1665.	7.3	93
48	Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity But Develop Fewer Hepatocellular Carcinomas Following Chronic Liver Injury. <i>Gastroenterology</i> , 2020, 158, 1698-1712.e14.	1.3	55
49	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	2.4	136
50	Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline <i>CDH1</i> Variants. <i>Cancer Research</i> , 2020, 80, 2114-2124.	0.9	21
51	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 551-559.e1.	4.4	131
52	Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	3.6	18
53	Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3428-3436.	4.1	41
54	The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. <i>Cancers</i> , 2019, 11, 1441.	3.7	17

#	ARTICLE	IF	CITATIONS
55	Current Pattern of Use and Impact of Pringle Maneuver in Liver Resections in the United States. Journal of Surgical Research, 2019, 239, 253-260.	1.6	14
56	Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. Nature Communications, 2019, 10, 1473.	12.8	71
57	Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. Cell, 2019, 177, 608-621.e12.	28.9	167
58	Neuroendocrine Tumors in Meckel's Diverticulum: Recommendation for Lymphadenectomy Regardless of Tumor Size Based on the NCDB Experience. Journal of Gastrointestinal Surgery, 2019, 23, 679-685.	1.7	12
59	Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. Journal of Surgical Oncology, 2019, 119, 303-317.	1.7	40
60	Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population. Annals of Surgical Oncology, 2019, 26, 167-176.	1.5	5
61	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15
62	Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study. Annals of Surgical Oncology, 2018, 25, 1193-1201.	1.5	33
63	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology, 2018, 154, 1706-1718.e1.	1.3	695
64	Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2907-2913.	2.4	50
65	Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Gastroenterology, 2018, 154, 1421-1434.	1.3	88
66	Minimally Invasive Versus Open Pancreaticoduodenectomy. Annals of Surgery, 2018, 268, 151-157.	4.2	97
67	Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer. JAMA Oncology, 2018, 4, 31.	7.1	60
68	Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study. Cancer, 2018, 124, 1122-1131.	4.1	10
69	Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma. Cancer, 2018, 124, 743-751.	4.1	37
70	Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. Journal of Gastrointestinal Surgery, 2018, 22, 695-702.	1.7	40
71	ASO Author Reflections: Use of Retrospective Administrative Datasets in Rare Cancer Subtypes to Determine the Efficacy of Adjuvant Therapy. Annals of Surgical Oncology, 2018, 25, 798-799.	1.5	0
72	The prognostic significance of adrenocortical carcinomas identified incidentally. Journal of Surgical Oncology, 2018, 118, 1155-1162.	1.7	6

#	ARTICLE	IF	CITATIONS
73	Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 2080-2087.	1.7	11
74	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2308-2315.	1.5	19
75	Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. <i>Journal of Surgical Oncology</i> , 2018, 118, 21-30.	1.7	38
76	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. <i>VideoEndocrinology</i> , 2018, 5, .	0.1	0
77	Curative Surgical Resection of Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 197-204.	4.2	38
78	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 756-758.	4.4	1
79	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017, 130, 1099-1106.e1.	1.5	99
80	Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1758-1760.	1.5	2
81	Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma. <i>Current Hepatology Reports</i> , 2017, 16, 146-151.	0.9	0
82	Reply. <i>Hepatology</i> , 2017, 66, 1002-1003.	7.3	3
83	Robotic Versus Laparoscopic Pancreaticoduodenectomy: a NSQIP Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1784-1792.	1.7	68
84	Nomogram to predict non-home discharge following pancreaticoduodenectomy in a national cohort of patients. <i>Hpb</i> , 2017, 19, 1037-1045.	0.3	11
85	Conversion of Minimally Invasive Distal Pancreatectomy: Predictors and Outcomes. <i>Annals of Surgical Oncology</i> , 2017, 24, 3725-3731.	1.5	43
86	Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. <i>Cancer Cell</i> , 2017, 32, 574-589.e6.	16.8	172
87	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1196-1205.	7.3	188
88	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 352-362.	1.7	27
89	Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 875-884.	7.3	129
90	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. <i>American Surgeon</i> , 2017, 83, 761-768.	0.8	12

#	ARTICLE	IF	CITATIONS
91	Medical Management of Hepatocellular Carcinoma. Journal of Oncology Practice, 2017, 13, 356-364.	2.5	42
92	Management of hepatocellular in the United States. Chinese Clinical Oncology, 2017, 6, 21-21.	1.2	26
93	Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?. Cancer, 2016, 122, 2454-2456.	4.1	0
94	Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. American Journal of Gastroenterology, 2016, 111, 967-975.	0.4	39
95	Commentary: Liver regeneration after major hepatectomy: Impact of body mass index. Surgery, 2016, 160, 92-93.	1.9	0
96	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Annals of Surgical Oncology, 2016, 23, 583-591.	1.5	18
97	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
98	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
99	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. Journal of the American College of Surgeons, 2016, 223, 794-803.	0.5	24
100	Actual 10-year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
101	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.5	71
102	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
103	Advances in Local and Systemic Therapies for Hepatocellular Cancer. Current Oncology Reports, 2016, 18, 9.	4.0	14
104	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
105	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
106	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
107	A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2016, 14, 295-300.	4.4	31
108	Diagnostic Delays Are Common Among Patients With Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 543-549.	4.9	40



#	ARTICLE	IF	CITATIONS
109	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 164-172.	1.7	36
110	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. <i>Nature Communications</i> , 2015, 6, 6744.	12.8	879
111	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2154-2161.	1.7	2
112	Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?. <i>Digestive Diseases</i> , 2015, 33, 642-647.	1.9	17
113	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. <i>American Journal of Medicine</i> , 2015, 128, 90.e1-90.e7.	1.5	128
114	Primary Gastric Melanoma: Case Report of a Rare Malignancy. <i>Rare Tumors</i> , 2015, 7, 46-49.	0.6	18
115	Conversion Chemotherapy for Unresectable Colorectal Liver Metastases: Are We Making a Difference?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 160-167.	0.5	4
116	Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 231-240.	0.5	0
117	Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1075-1082.	1.5	22
118	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 791-798.e1.	4.4	86
119	Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome. <i>Annals of Surgical Oncology</i> , 2014, 21, 1287-1295.	1.5	182
120	Epithelial to Mesenchymal Transition Expression Profiles as Predictive Biomarkers of Recurrence Following Resection of HCC: Implications for Current Clinical Use and Future Stratification for Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3723-3724.	1.5	6
121	Factors That Affect Accuracy of Î±-Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 870-877.	4.4	109
122	Does Surveillance for Hepatocellular Carcinoma Benefit Patients With Compensated Cirrhosis?. <i>Gastroenterology</i> , 2014, 147, 935-936.	1.3	1
123	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 325-334.	0.4	270
124	Percutaneous cholecystostomy: the challenges of cohort analysis. <i>Journal of Surgical Research</i> , 2014, 190, 417-418.	1.6	5
125	An Essential Mesenchymal Function for miR-143/145 in Intestinal Epithelial Regeneration. <i>Cell</i> , 2014, 157, 1104-1116.	28.9	188
126	Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 332-332.	1.6	1



#	ARTICLE	IF	CITATIONS
127	Laparoscopic liver resection for hepatocellular carcinoma: Indications and role. Clinical Liver Disease, 2012, 1, 206-208.	2.1	2
128	Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection. Clinical Gastroenterology and Hepatology, 2012, 10, 1284-1290.	4.4	15
129	CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2012, 19, 339-346.	1.5	43
130	Hepatocellular Carcinoma Surveillance: All Cirrhotic Patients May Not Be Equal. Gastroenterology, 2012, 143, 1393-1395.	1.3	2
131	Invasive Carcinoma Arising in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2011, 253, 968-974.	4.2	107
132	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Annals of Surgical Oncology, 2011, 18, 2192-2199.	1.5	76
133	Preface. Surgical Oncology Clinics of North America, 2010, 19, xv-xvii.	1.5	2
134	Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World Journal of Gastrointestinal Surgery, 2010, 2, 359.	1.5	22